Every 8-K that Mimedx Group Inc (MDXG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MDXG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDXG filings page.
MiMedx Group, Inc. filed an amendment to correct termination fee amounts in its previously disclosed Agreement and Plan of Merger with Sanara MedTech Inc.. The amendment clarifies that Sanara would owe MiMedx a termination fee of $9,660,336.00 in specified circumstances, and MiMedx would owe Sanara $22,540,785.00 if it fails to consummate the merger when required.
Under the merger agreement, Sanara stockholders will receive per share merger consideration of $33.00 in cash plus 0.4735 shares of MiMedx common stock, with the stock portion valued at $2.00 per share based on MiMedx’s five-day average closing price before July 29, 2026. All Sanara common shares (other than excluded and appraisal shares) will be converted into this mixed cash-and-stock consideration, and MiMedx shares to be issued will be listed on Nasdaq.
MiMedx obtained a $300.0 million first lien senior secured term loan commitment from funds managed and/or advised by Hayfin Capital Management LLP to support the transaction and will terminate and repay its existing credit agreement upon closing of the new financing. A voting agreement with certain Sanara stockholders covers approximately 38.9% of Sanara’s voting power, supporting approval of the merger. Closing remains subject to Sanara stockholder approval, antitrust clearance, SEC effectiveness of a Form S-4 registration statement, Nasdaq listing approval for the new MiMedx shares, absence of a Material Adverse Effect on Sanara, and other customary conditions. The merger agreement includes an outside date of July 29, 2027, extendable to January 29, 2028 if antitrust approvals are outstanding.
MiMedx Group reported second quarter 2026 net sales of $64.4 million, down 35% from $98.6 million a year earlier, as Surgical revenue grew 15% to $39.3 million but was more than offset by a 61% decline in Wound revenue to $25.1 million following Medicare reimbursement changes. Gross profit was $44.4 million, with gross margin falling to 69% from 81% due mainly to lower Wound pricing, product mix, and restructuring-related costs.
Selling, general and administrative expense was $59.8 million versus $64.2 million, reflecting cost reductions but higher bad debt, while R&D was $2.8 million. The company posted a net loss of $14.8 million, compared with $9.6 million of net income a year earlier; Adjusted EBITDA was a loss of $8.1 million versus positive $24.2 million, a margin swing to -12.6%. Cash and cash equivalents were $135.8 million at June 30, 2026, with net cash of $119 million.
MiMedx reiterated its 2026 net sales outlook of $260–$290 million and expects Adjusted EBITDA to approach breakeven for the year, while longer term targeting low double-digit annual net sales growth and an Adjusted EBITDA margin above 20%. It also agreed to acquire Sanara MedTech in a cash-and-stock deal valued at $35 per share, implying enterprise value of about $350 million. Sanara holders will receive $33.00 in cash and 0.4735 MiMedx shares (valued at $2.00 per Sanara share), funded with cash on hand and a new $300 million term loan. Boards of both companies unanimously approved the deal, which is expected to close by year-end 2026 subject to Sanara shareholder and regulatory approvals. Management projects combined revenue well above $400 million in the first full year post-close, more than $20 million of 2027 cost synergies, and an Adjusted EBITDA margin above 20%.
MiMedx Group, Inc. agreed to acquire Sanara MedTech Inc. in a cash-and-stock merger valuing Sanara at $35 per share, or approximately $350 million. Sanara shareholders will receive $33.00 in cash plus 0.4735 shares of MiMedx common stock per Sanara share, a 46% premium to Sanara’s 30-day volume-weighted average price.
MiMedx obtained a fully committed $300 million first lien senior secured term loan from Hayfin to fund the cash portion and will terminate its existing credit agreement at closing. The boards of both companies unanimously approved the deal, which is subject to Sanara stockholder approval, antitrust clearance under the Hart-Scott-Rodino Act, SEC effectiveness of a Form S-4, Nasdaq listing of the new MiMedx shares, and other customary conditions.
Management expects the combination to nearly double MiMedx’s surgical revenue and to generate 2027 total revenue well above $400 million, with Adjusted EBITDA margin above 20% and over $20 million of annual run-rate cost synergies. Voting agreements already cover about 38.9% of Sanara’s voting power.
MiMedx Group, Inc. reported governance updates and 2026 annual meeting results. The board amended the Amended & Restated Bylaws to allow the chief executive officer to serve on up to three boards of directors of public companies.
At the 2026 Annual Meeting, 125,360,965 common shares, representing approximately 84.2% of eligible votes, were present in person or by proxy. Shareholders re‑elected the nominated directors, approved an advisory resolution on executive compensation, and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
MiMedx Group, Inc. reported first quarter 2026 net sales of $59 million, down 33% from $88 million a year earlier, as new Medicare reimbursement rules severely pressured its Wound segment. Surgical product sales grew 13% year over year to $36.4 million, while Wound sales fell 60% to $22.6 million.
Gross margin declined to 71% from 81%, mainly due to lower Wound pricing and unfavorable mix. The company posted a net loss of $10.9 million, versus $7.0 million of net income in 2025, and Adjusted EBITDA was a loss of $11.6 million, a margin of negative 19.7%.
MiMedx ended March 31, 2026 with $159.8 million in cash and cash equivalents and net cash of $142 million. For 2026, it now expects net sales of $260–$290 million and approximately breakeven Adjusted EBITDA, and continues to target low double-digit annual net sales growth with Adjusted EBITDA margin above 20% longer term.
MiMedx Group, Inc. launched a restructuring and cost reduction initiative to streamline operations and support future profitability. The plan targets approximately $40 million in annualized operating expense savings across the company and will result in a one-time restructuring charge of about $4 million in the second quarter of 2026.
As part of the changes, the position of Chief Operating Officer held by Ricci Whitlow was eliminated; her departure is stated as not due to a disagreement with the company. CEO Joe Capper’s base salary was reduced by 20%, while base salaries for other named executive officers were reduced by 10% through December 31, 2026.
Management notes that the Surgical business is performing well, but the Wound Care business is recovering slowly following a January 1 Medicare reimbursement reduction, prompting the decision to adjust the cost structure.
MiMedx Group, Inc. reported record fourth-quarter and full-year 2025 results, with net sales of $118.1 million for the quarter, up 27% year-over-year, and $418.6 million for the year, up 20%. Growth was driven by Wound sales rising 28% in Q4 and Surgical sales up 25%, supported by new products like EPIXPRESS, EMERGE and strong AMNIOFIX and AMNIOEFFECT performance.
Fourth-quarter GAAP net income was $15.2 million, or $0.10 per diluted share, while Adjusted EBITDA reached $29.4 million, a 24.9% margin. For 2025, GAAP net income was $48.6 million and Adjusted EBITDA was $105.7 million, representing a 25.3% margin. Gross margin stayed above 82% on a GAAP basis and 85% on an adjusted basis for the year.
Cash and cash equivalents were $166.1 million at December 31, 2025, with net cash of $148 million after debt, up $63 million year-over-year. The board authorized a share repurchase program of up to $100 million over two years. For 2026, MiMedx estimates net sales of $340–360 million and expects an Adjusted EBITDA margin in the mid-to-high teens, reflecting anticipated Medicare reimbursement changes that may pressure near-term Wound revenue.
MiMedx Group, Inc. filed a Form 8-K to share that it updated its investor presentation on January 12, 2026, furnishing the slide deck as Exhibit 99.1 under Regulation FD. The materials include forward-looking statements about future sales and sales growth, 2026 and longer-term financial goals such as net sales, Adjusted EBITDA, margins, corporate expenses and cash, as well as expectations for the placental tissue market, Medicare spending and growth across care settings. The company highlights numerous risks that could cause actual results to differ and notes it has no obligation to update these forward-looking statements after the date of the report.
MiMedx Group (MDXG) furnished its quarterly results update. The company announced it issued a press release with financial results for the quarter ended September 30, 2025, and furnished it under Item 2.02. The materials include an Earnings Press Release (Exhibit 99.1), an Earnings Call presentation (Exhibit 99.2), and an Investor Presentation (Exhibit 99.3).
Management scheduled a conference call and webcast on October 29, 2025, at 4:30 PM Eastern Daylight Time to discuss the quarter. The information in Items 2.02 and 7.01 is furnished, not filed, under the Exchange Act.
MiMedx Group, Inc. (MDXG) disclosed that it will participate in the Cantor Global Healthcare Conference on September 3, 2025 and has updated its investor presentation. The presentation materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated by reference. The filing reiterates standard forward-looking statement language, noting that actual results may differ due to risks such as uncertain future sales, reimbursement dynamics, scientific outcomes, international commercialization challenges, and regulatory developments. The disclosure clarifies that the furnished information is not deemed "filed" for certain Exchange Act liabilities and is not automatically incorporated into other securities filings.
MiMedx Group, Inc. (NASDAQ: MDXG) filed an 8-K summarizing the voting results of its 2025 Annual Meeting held on 18 June 2025. Shareholder participation was strong with 126.6 million shares (≈85.7% of the shares entitled to vote) represented in person or by proxy.
Key outcomes:
- Board elections: All nine incumbent directors were re-elected. Support ranged from 90.5 million to 97.2 million votes for, versus 4.5-10.3 million against. Broker non-votes totaled 24.7 million.
- Say-on-Pay (advisory): 94.8 million votes for, 6.9 million against, 0.2 million abstentions—about 93% approval.
- Auditor ratification: Deloitte & Touche LLP was confirmed with 123.7 million votes for and less than 1.0 million against (≈97% support).
- 2016 Equity & Cash Incentive Plan amendment: Approved with 91.4 million votes for (≈90% support) and 10.3 million against.
- Say-on-Pay frequency: A majority of 97.5 million shares favored an annual advisory vote; consequently, the company will hold future Say-on-Pay votes every year.
The filing contained no financial performance data or transactional announcements, focusing solely on corporate-governance matters. Overall, the company secured broad shareholder endorsement on all proposals, though c. 10% opposition on compensation-related items indicates a modest level of investor dissent that management may monitor going forward.